Chapel Hill, North Carolina 27599


This is a single arm, single center study of 15 patients with brain lesions being treated at UNC Hospitals. Subjects will undergo one (1) FLT-PET-MRI scan before their scheduled surgical biopsy of their brain lesion(s).

Study summary:

Identifying imaging biomarkers of metastatic brain tumor treatment response could allow early modification of treatment by determination of tumor progression vs. treatment related effects (pseudo-progression, radiation necrosis). Earlier treatment response assessment could reduce cost, improve clinical trial efficiency and allow better assessment of prognosis. The development of PET/MRI offers the possibility of combining the functional imaging of PET with the exquisite soft tissue contrast and physiologic imaging capabilities of MRI. Combining FLT-PET imaging with MRI may allow better evaluation of new and unclear lesions in brain metastatic disease. The goal of this study is to explore FLT-PET imaging combined with dynamic MR imaging techniques for the identification of tumor response markers in metastatic brain tumors.


Inclusion Criteria: - Known brain lesion in central nervous system (CNS) scheduled to have surgical biopsy of the lesion, identified by the UNC Brain Tumor Board as having clinical question of radiation necrosis vs. recurrence - At least one measurable lesion greater than 1 cm in diameter - ≥ 18 years of age - Study-specific informed consent reviewed and signed Exclusion Criteria: - Pregnant, nursing, or planning to become pregnant within 30 days of anticipated PET-MRI scan - Condition that makes MRI unsafe (e.g., cardiac pacemaker, epicardial pacemaker leads, cochlear implants, metal aneurysm clips, metal halo devices) - Inability to tolerate MRI (e.g., unable to lie flat for > 1 hour, severe claustrophobia) - Allergy to MRI contrast agent (Magnevist, Multihance, Ablavar, Dotarem, Eovist, Gadavist) - Known allergy to fluorothymidine - Study participation would cause significant delay (> 2 weeks) in scheduled standard of care therapy - Creatinine clearance < 60 ml/min, as estimated by the Cockcroft-Gault formula - Body Mass Index (BMI) > 35 - Poorly controlled diabetes mellitus (fasting blood glucose > 200 mg/dl)



Primary Contact:

Principal Investigator
Yueh Lee, MD/PhD
University of North Carolina, Chapel Hill

Soma Prum
Phone: 919-843-9245

Backup Contact:

Kristine Baluyot
Phone: 919-843-5420

Location Contact:

Chapel Hill, North Carolina 27599
United States

Kristine Baluyot
Phone: 919-843-5420

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.